Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice

Sibaud, V.; Sollena, P.

doi:10.1016/j.annder.2022.11.013

Cited by 7 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While prior studies have specifically focused on palbociclib-related CAEs, 19 few studies have been carried out on ribociclib-induced CAEs beyond phase III trials and case reports. 18 , 22 , 24-26 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication

Borroni,

Bartolini,

Gaudio

et al. 2024

The Oncologist

View full text Add to dashboard Cite

Background Ribociclib is approved for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer (ABC) treatment, in combination with endocrine therapy. Hematological, hepatic, and cardiac adverse events (AEs) emerged from pivotal trials, but little is known about cutaneous adverse events (CAEs). Patients and Methods We report data from a retrospective cohort study of all patients with HR+/HER2− ABC treated with ribociclib at Humanitas Cancer Center between June 2017 and December 2022. We recorded clinical-pathological data, the incidence, and treatment of ribociclib-related CAEs. These were evaluated according to the NCI-CTCAE v5.0 classification. Progression-free survival (PFS) was estimated by Kaplan-Meier method and the log-rank test was used to analyze differences between groups. Results Thirteen of 91 patients (14.3%) experienced treatment-related CAEs (mean time to the occurrence: 3.9 months). The most frequent CAEs were eczematous dermatitis (53.8%) and maculo-papular reaction (15.4%). Itch was reported by all 13 patients. The grade was G3 in 8 cases, G2 in 4, and G1 in 1. An integrated approach based on ribociclib dose modulation and dermatological interventions (oral antihistamine, moisturized cream, topical, and/or systemic steroids) could prevent ribociclib discontinuation in most patients. At a median follow-up of 20 months, the median PFS was 13 months (range, 1-66) with a better PFS curves for patients experiencing CAEs (P = .04). Conclusion We mapped frequency and types of ribociclib-induced CAEs. An interdisciplinary management of CAEs incorporated into routine care may reduce the rate of drug discontinuation thus potentially contributing to better long-term outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

“… 2 , 6 , 23 While pivotal trials only reported unspecific cases of mild CAEs, a wide range of dermatological manifestations, including severe ones, have been described with ribociclib in various case reports and series in literature. 24-26 …”

Section: Introductionmentioning

confidence: 99%

Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication

Borroni,

Bartolini,

Gaudio

et al. 2024

The Oncologist

View full text Add to dashboard Cite

show abstract

“…The main side effects of this treatment are gastrointestinal and hematological toxicity [ 6 ]. It can also lead to some cutaneous events, such as alopecia, rash, pruritus, vitiligo-like lesions, or cutaneous lupus erythematosus [ 7 , 8 ]. To our knowledge, no case of DRESS syndrome with ribociclib has been published to date.…”

Section: Introductionmentioning

confidence: 99%

Case Report of Probable DRESS Syndrome Associated with Ribociclib

Carneiro,

Bove,

Beau-Salinas

et al. 2023

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but known and potentially severe side effect of drugs. The recent development of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as ribociclib, has considerably improved the management of hormone receptor positive (HR+) and HER2 negative (HER2-) advanced breast cancer. Here, we present the case of an 83-year-old patient who developed a probable DRESS syndrome induced by ribociclib, presenting with fever, eosinophilia, rash, and hepatic cytolysis. The RegiSCAR score was 4. The symptomatology evolved favorably with topical and systemic corticosteroids, without any sequel. Another CDK4/6 inhibitor, palbociclib, was introduced later without any cross-toxicity and with an excellent therapeutic response for more than 3 years.

show abstract

Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience

Starace,

Rapparini,

Cedirian

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice

Cited by 7 publications

References 30 publications

Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication

Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication

Case Report of Probable DRESS Syndrome Associated with Ribociclib

Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience

Contact Info

Product

Resources

About